Binkie4
Senior Member (Voting Rights)
https://www.telegraph.co.uk/news/20...t-cells-gives-better-immune-response-current/
Article is about AZ creating a new vaccine that gives a better response by focusing on the T cells.
Co- vac1 has strong phase 1 trial results.
. "The team suggested the vaccine would make for an effective complementary vaccine, particularly for the elderly and immunocompromised, alongside the currently approved jabs."
edit: phase 1 results were based on data from only 36 people. Are phase 1 trials usually as small as this?
edit 2: if this vaccine is aimed at the immunocompromised, I hope they have secure methods of ensuring that the trials contain adequate numbers of this type of patient for safety reasons. Can anyone advise on how this is dealt with.
Article is about AZ creating a new vaccine that gives a better response by focusing on the T cells.
Co- vac1 has strong phase 1 trial results.
. "The team suggested the vaccine would make for an effective complementary vaccine, particularly for the elderly and immunocompromised, alongside the currently approved jabs."
edit: phase 1 results were based on data from only 36 people. Are phase 1 trials usually as small as this?
edit 2: if this vaccine is aimed at the immunocompromised, I hope they have secure methods of ensuring that the trials contain adequate numbers of this type of patient for safety reasons. Can anyone advise on how this is dealt with.
Last edited: